Clinical trial Recruiting at 1 site Interventional Ages 18 to 75

Improving heart function in patients with Chagas disease

Official title: Clinical and Functional Effects of Cardiac Contractility Modulation in Chagas Heart Disease: a Randomized Study - Contractility - FIX-Chagas

Run by InCor Heart Institute · NCT05519046 · Data updated 2026-11-12

This study is testing whether a new heart treatment called cardiac contractility modulation can help people with heart failure from Chagas disease feel better compared to a different treatment called cardiac resynchronization therapy.

Quick facts

Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment60 (estimated)
SponsorInCor Heart Institute
Academic / other
Locations1 site (São Paulo, São Paulo)
StatusRecruiting
StartedMay 25, 2022
Main results expectedDecember 31, 2027
Study endsDecember 31, 2027
Registry record updatedJuly 8, 2026
Trial IDNCT05519046 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-75 with documented Chagas disease and advanced heart failure characterized by severe systolic dysfunction.

Probably not a fit

Patients with other significant cardiovascular diseases or those with kidney or liver dysfunction may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of cardiac contractility modulation (CCM) as an adjuvant treatment for heart failure in patients suffering from chronic Chagas cardiomyopathy (CCC). It aims to compare the clinical and functional responses of patients receiving CCM device implantation against those undergoing cardiac resynchronization therapy (CRT). The study focuses on individuals with advanced heart failure, severe systolic dysfunction, and specific conduction patterns, utilizing a randomized approach to assess outcomes. The research is particularly relevant given the high prevalence of Chagas disease in Latin America and its emerging significance in other regions.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option that significantly improves heart function and quality of life for patients with Chagas disease.

How similar studies have gone: While there is limited evidence on the use of CCM specifically for CCC, similar approaches in heart failure management have shown promise in other contexts.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Signing of an informed consent form (ICF) before randomization and any study procedure,
* Both genders, age \>18 years and \<75 years,
* Recent positive (last two years) and documented serology for Chagas disease, in at least two different tests (indirect hemagglutination, indirect immunofluorescence, or ELISA),
* NYHA II-III heart failure functional class,
* LVEF\< 35%,
* Non left bundle branch block
* Intraventricular desynchrony (Yu index)
* Global longitudinal strain \>11 %.

Exclusion Criteria:

* Participation in another study, presently or terminated \<1 year ago, except for a totally unrelated observational study,
* Other concomitant cardiovascular diseases, including uncontrolled diabetes mellitus (systemic arterial hypertension without permitted target organ compromise),
* Kidney dysfunction (serum creatinine \>1.5mg/dL or eGFR \<30mL/min/1.73m2) or liver dysfunction, with diagnosis of cirrhosis or portal hypertension or elevated serum enzymes (AST or ALT) \> 3x the upper limit of normality,
* Moderate or severe chronic obstructive pulmonary disease,
* Peripheral polyneuropathy,
* Hyperthyroidism,
* Current alcoholism or not abandoned for \>2 years,
* Diagnosed with psychopathy or psychosis or addiction to illicit drugs,
* Life expectancy \<1 year, due to the disease itself or comorbidities (including NYHA class IV),
* Pregnancy or breastfeeding,
* Potential to become pregnant during the study (non-menopausal patients who have not undergone a radical and safe contraceptive process),
* Previously withdrawn from this study.

Where it's running

  • InCor - HCFMUSP
    São Paulo, São Paulo, Brazil
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.